homepagevideoimage.jpg
 

Transforming
Therapies for Life

 

About TerSera™ Therapeutics

TerSera Therapeutics LLC acquires and develops specialty pharmaceutical products with a focus on select therapeutic areas.

Our mission is to market products which truly make a difference for patients.

Our focus is to bring intelligent solutions to prescribers and patients who need better solutions.

We deliver a comprehensive set of programs that go beyond the therapy itself in order to provide improved outcomes for patients.

For more information about TerSera™ Therapeutics, please contact us.

About GTCR

Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Financial Services & Technology, Healthcare, Technology, Media & Telecommunications and Growth Business Services industries. The Chicago-based firm pioneered The Leaders Strategy™ - finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $12 billion in over 200 companies. For more information, please visit www.gtcr.com.

 

TerSera News

February 20, 2017
AstraZeneca announced today that it has entered into an agreement with TerSera Therapeutics LLC (“TerSera”) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. This transaction is expected to close during Q1 of 2017.

February 4, 2016
GTCR Announces Third Partnership with Ed Fiorentino to Form TerSera™ Therapeutics

Therapeutic Experience

The TerSera team has significant collective specialty pharmaceutical experience. We have worked with compounds in all phases of pre-clinical and clinical development, as well as lifecycle management and phase IV studies.


Therapeutic areas of interest include, but are not limited to:

  • Allergy/Immunology

  • CNS Disorders

  • Endocrinology

  • Gastroenterology

  • Infectious Disease

  • Oncology

  • Orphan Diseases

  • Rheumatology

  • Transplant-Related Therapies

  • Urology

  • Women’s Health

The TerSera Leadership

Edward J. Fiorentino
Chairman and Chief Executive Officer

Ed Fiorentino is Chairman of the Board and CEO of TerSera Therapeutics. Previously, Ed was Chairman of the Board and CEO of specialty pharmaceutical company Crealta Pharmaceuticals, and CEO of Actient Pharmaceuticals.

Prior to Crealta and Actient, Ed was with Abbott for more than 20 years. His senior-level management experience at Abbott includes Corporate Vice President of pharmaceutical commercial operations; Senior Vice President and President of Abbott Diabetes Care; and Executive Vice President of TAP Pharmaceuticals, an Abbott joint venture with Takeda Pharmaceuticals. Ed began his career with Bristol-Myers.

Ed currently serves on the board of TerSera Therapeutics and the board of Senseonics. He previously served on the boards of Crealta Pharmaceuticals, Actient Pharmaceuticals, TAP Pharmaceuticals, Graceway Pharmaceuticals, iBIO, California Healthcare Institute, National Pharmaceutical Council and Allendale Association. Ed holds a B.S. in Business Administration from the State University of New York and an M.B.A. from Syracuse University.


bio_mark.jpg

Mark Tatro
Executive Vice President, Chief Financial Officer

Mark Tatro is Executive Vice President and Chief Financial Officer of TerSera Therapeutics.

Previously, Mark was Chief Financial Officer of specialty pharmaceutical companies Crealta Pharmaceuticals and Actient Pharmaceuticals.

Prior to Crealta and Actient, Mark was the General Manager of Abbott Diabetes Care in Toronto. He also worked for a number of years as division Vice President and Controller for Abbott Diabetes Care in Alameda, Calif.

Previous career highlights include Vice President of Finance for TheraSense, Inc.; Vice President of Finance for Gatan Inc., and Corporate Controller for Roper Industries, Inc.

Mark earned a B.S. in accounting from Florida State University and graduated Magna Cum Laude.


Richard Crowley
Executive Vice President, Operations and Quality Assurance

Richard Crowley is Executive Vice President, Operations and Quality Assurance of TerSera Therapeutics. 

Previously, Rick was Senior Vice President, Operations and Quality Assurance at Crealta Pharmaceuticals, responsible for quality assurance, technical operations and regulatory affairs.

Prior to Crealta, Rick was Senior Vice President of Biopharmaceutical Operations and COO at Savient Pharmaceuticals. Rick was responsible for all quality assurance, regulatory affairs, technical operations and supply chain management and project management activities.

Prior to joining Savient, Rick served as Senior Vice President, Biopharmaceutical Operations at ImClone Systems, wholly owned subsidiary of Eli Lilly and Company. In that role, he was responsible for the clinical and commercial manufacturing of ImClone's products along with process and analytical development, engineering, facilities, logistics and validation. Prior to joining ImClone, Rick held several management-level positions at BASF Bioresearch Corp., and held technical positions at Genencor International, Eastman Kodak Company and Monsanto. 

Rick earned a Bachelor of Science degree in chemistry from Denison University and a Master of Science degree in chemical engineering from the University of Pennsylvania.


Edward Donovan
Executive Vice President, General Counsel and Secretary

Edward Donovan is Executive Vice President, General Counsel and Secretary of TerSera Therapeutics.

Previously, Edward was General Counsel and Secretary of specialty pharmaceutical companies Crealta Pharmaceuticals and Actient Pharmaceuticals. At Crealta and Actient, Edward led all legal and corporate governance functions, including litigation, government affairs, intellectual property, and transactional and commercial law, as well as overseeing the companies’ compliance programs.

Prior to Actient, Edward was a partner in the Chicago office of the law firm Kirkland & Ellis LLP.  At Kirkland, he specialized in mergers and acquisitions, private equity and corporate law, and completed numerous pharmaceutical and other healthcare-related transactions.

Edward holds a bachelor of science from the United States Military Academy at West Point and a J.D. from the University of Virginia School of Law. He is licensed to practice law in the state of Illinois.


Nancy Joseph-Ridge, M.D.
Executive Vice President, Chief Medical Officer

Nancy has more than 25 years of experience in academic clinical research and the pharmaceutical industry. Previously, Nancy was at Takeda with senior level management experience that included being a Corporate Officer and an R&D Executive. She was head of CNS, Immunology and Rheumatology therapeutic areas, responsible for all strategic aspects of R&D for those areas. She was also head of Global Development and was responsible for all aspects of drug development of pipeline and marketed compounds, including clinical sciences, clinical operations, medical, regulatory, pharmacovigilance, project management and quality.

Prior to that, Nancy was President Takeda Global R&D U.S., Vice-President of R&D at TAP Pharmaceuticals, and she held various positions in clinical development at Searle/Pharmacia.

Prior to working in the pharmaceutical industry, she was an Assistant Professor of Medicine at Rush Medical Center and an Assistant Professor of Clinical Medicine at University of Chicago.

Nancy previously served on the Board of iBIO Institute and was chairperson for two years. She also served on the PhRMA Scientific and Regulatory Committee and Chicago Technology Industry Diversity Council. 

Nancy received her medical degree from University of Illinois, completed internship and residency in Internal Medicine and was chief resident at Rush Medical Center and then completed fellowship in Rheumatology at University of Chicago. She received Board certifications in Internal Medicine and Rheumatology. Nancy has been a member of various professional societies and is currently a Fellow Member of the American College of Rheumatology.


Vicky Papoutsis
Executive Vice President, Business Development

Vicky Papoutsis is Executive Vice President, Business Development, of TerSera Therapeutics. 

Previously, Vicky led business development efforts at specialty pharmaceutical companies Crealta Pharmaceuticals and Actient Pharmaceuticals.

Prior to Crealta and Actient, Vicky was the Senior Director of International Operations for Takeda Pharmaceuticals, where she was responsible for all local licensee management and territory expansion in the Asia Pacific region. She also served as Director of Global Licensing and Business Development.   

Prior to Takeda, Vicky worked for a number of years as Director of Licensing and Business Development at TAP Pharmaceuticals, a Takeda and Abbott joint venture.

Additional career highlights include various legal positions in general litigation, including insurance defense, medical malpractice defense, credit reporting and breach of contract.

Vicky earned a B.A. in English from the University of Michigan, a J.D. from the University of Illinois and an M.B.A. from the University of Chicago. She is licensed to practice law in the state of Illinois.


Bryan Reiners
Executive Vice President, Business Insights

Bryan Reiners is Executive Vice President, Business Insights of TerSera Pharmaceuticals. 

Previously, Bryan held a similar position at Crealta Pharmaceuticals and Actient Pharmaceuticals.

Prior to Crealta and Actient, Bryan was with Astellas Pharma, US Inc., as Director of Forecasting and Market Analytics, where he was responsible for all aspects of forecasting, business/market planning and analysis for all on-market products and products awaiting regulatory approval. 

Prior to Astellas, Bryan spent almost 17 years with Abbott in various finance, market research, and forecasting roles; including Director of Forecasting for Abbott Diabetes Care. Prior to Abbott, Bryan worked for KPMG’s audit practice in Minneapolis.

Bryan holds a B.A. in Accounting and Business Administration from Wartburg College in Iowa and a Masters of Accountancy from St. Cloud State in Minnesota. Bryan is also a Certified Public Accountant.


bio_charlie.jpg

Charlie Tobler
Executive Vice President, Commercial Operations

Charlie Tobler is Executive Vice President, Commercial Operations of TerSera Therapeutics. 

Previously, Charlie was the Head of Commercial Operations for Crealta Pharmaceuticals and Actient Pharmaceuticals.  

Prior to Crealta and Actient, Charlie was Vice President and Franchise Leader for Takeda's Global Cardiovascular and Metabolic (CVM) franchise. In that role, he led strategic planning and business development targeting for Takeda's global CVM business. He also served as Vice President of Diabetes Marketing for Takeda Pharmaceuticals North America. 

Prior to Takeda, he spent four years in marketing and business development at TAP Pharmaceuticals. Prior to TAP, he spent 14 years with Eli Lilly and Company, where he held various sales and marketing positions.

Charlie holds a B.S. Pharm. Degree in Pharmacy from the University of Iowa and an M.B.A. from The Kelley School of Business at Indiana University. Charlie is also a registered pharmacist.

Business Development

 

Please contact us to discuss possible partnership opportunities with
TerSera Therapeutics.

 

Interested in learning more about TerSera Therapeutics?

 

For general inquiries, media information, or new business opportunities please complete and submit the contact form below.

* Required information

Name *
Name
Phone Number *
Phone Number

Corporate and Administrative Offices

TerSera Therapeutics LLC
305 Second Avenue SE
Suite 205
Cedar Rapids, IA 52401
(319) 409-1648

 

TerSera Therapeutics LLC
Two Conway Park
150 N. Field Drive, Suite 195
Lake Forest, IL 60045
(888) 600-8116